Michael Lorsbach

  • Citations Per Year
Learn More
Very few reliable clinical data about the use of radioimmunotherapy in aggressive B-cell lymphoma exist. Patients with aggressive B-cell lymphoma registered in the international RIT-Network were analysed with regard to prior treatment, response and side effects. The RIT-Network is a web-based registry that collects observational data from(More)
Borderline ovarian tumour (BOT) represents a rare and special tumour entity. Despite a generally favourable prognosis for patients with BOT, the presence of invasive peritoneal implants decreases the survival rate to 30-50%. In contrast to ovarian cancer, only few data exist concerning the current clinical management of patients with BOT. For this reason,(More)
High-dose chemotherapy followed by Auto-SCT (ASCT) achieves prolonged disease-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma. Relapse, however, remains the most common cause of treatment failure and death. Several trials had documented significant benefit from radioimmunotherapy (RIT) with yttrium-90 (Y)-ibritumomab tiuxetan(More)
  • 1